{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125332","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.396182+00:00","generated_at":"2026-05-30T02:35:54.516343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance","bullets":["Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.","Net loss $17.1M ($0.17 loss per share) vs $63.6M ($0.65) YoY; cash & equivalents $160M sufficient into 2026.","Full-year guidance: total roxadustat net sales $330-350M; net product revenue $135-150M; cost plan substantially complete by year-end.","Pamrevlumab trials in pancreatic cancer (mPDAC and LAPC) failed primary endpoints; pipeline focus shifts to FG-3246 ADC.","FG-3246 Phase 2 combo study results expected 1H 2025; Phase 2 monotherapy trial starts Q1 2025; CIA approval decision early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125332","json":"https://secwatch.observer/filing/0000950170-24-125332.json","markdown":"https://secwatch.observer/filing/0000950170-24-125332.md","text":"https://secwatch.observer/filing/0000950170-24-125332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/0000950170-24-125332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:35:54.516343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}